Business Description
Compare
Compare
Traded in other countries / regions
978.GermanyADAG.USA IPO Date
2021-02-09Description
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.89 | |||||
| Equity-to-Asset | 0.63 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -0.62 | |||||
| Beneish M-Score | 0.39 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 79.4 | |||||
| 3-Year EBITDA Growth Rate | -61.5 | |||||
| 3-Year EPS without NRI Growth Rate | -52.6 | |||||
| 3-Year FCF Growth Rate | -38.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.93 | |||||
| 9-Day RSI | 38.05 | |||||
| 14-Day RSI | 40.22 | |||||
| 6-1 Month Momentum % | 28.41 | |||||
| 12-1 Month Momentum % | -59.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.1 | |||||
| Quick Ratio | 3.1 | |||||
| Cash Ratio | 2.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.3 |
Profitability Rank
| Name | Current | Vs Industry | Vs History |
|---|
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.91 | |||||
| PB Ratio | 0.58 | |||||
| Price-to-Tangible-Book | 0.58 | |||||
| EV-to-FCF | 1.88 | |||||
| Price-to-Net-Current-Asset-Value | 0.6 | |||||
| Price-to-Net-Cash | 0.64 |
How Adagene Inc (ADAG) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ADAG
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.825 | ||
| Beta | 0 | ||
| Volatility % | 85.11 | ||
| 14-Day RSI | 40.22 | ||
| 14-Day ATR ($) | 0.117576 | ||
| 20-Day SMA ($) | 1.59652 | ||
| 12-1 Month Momentum % | -59.82 | ||
| 52-Week Range ($) | 0.9 - 4.46 | ||
| Shares Outstanding (Mil) | 43.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Adagene Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Adagene Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Adagene Inc Frequently Asked Questions
What is Adagene Inc(ADAG)'s stock price today?
The current price of ADAG is $1.50. The 52 week high of ADAG is $4.46 and 52 week low is $0.90.
When is next earnings date of Adagene Inc(ADAG)?
The next earnings date of Adagene Inc(ADAG) is 2023-03-31 Est..
Does Adagene Inc(ADAG) pay dividends? If so, how much?
Adagene Inc(ADAG) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
